Education
About Us
Working with TipRanks
Follow Us
Xenon Pharmaceuticals (XENE)
:XENE
XENE Analyst Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
XENE Stock 12 Month Forecast
Average Price Target
$55.00
▲(62.82% Upside)
| Highest Price Target$65.00 | Average Price Target$55.00 | Lowest Price Target$42.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
Reiterated
04/16/25
Jefferies
Reiterated
04/15/25
Bank of America Securities
Reiterated
03/19/25
William Blair
Reiterated
03/17/25
TD Cowen
Reiterated
03/06/25
H.C. Wainwright
Reiterated
02/28/25
Wells Fargo
Reiterated
02/28/25
Wedbush
Reiterated
02/28/25
Deutsche Bank
Reiterated
02/28/25
Needham
Reiterated
02/28/25
Stifel Nicolaus
$62
Buy
83.54%
Upside
Reiterated
02/28/25
Stifel Nicolaus Remains a Buy on Xenon (XENE)
Leerink Partners
$50
Buy
48.02%
Upside
Reiterated
02/27/25
Promising Pipeline and Financial Stability Justify Buy Rating for Xenon
RBC Capital
$56
Buy
65.78%
Upside
Reiterated
02/26/25
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Eli Lilly & Co (NYSE: LLY) and Vaxcyte (NASDAQ: PCVX)
Robert W. Baird
$63
Buy
86.50%
Upside
Reiterated
11/12/24
Promising Prospects and Strategic Advances Drive Buy Rating for Xenon Pharmaceuticals
J.P. Morgan
―
Buy
―
Reiterated
10/24/24
Strong Growth Trajectory for Xenon Driven by Promising Clinical Pipeline and Differentiation Potential
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
Reiterated
04/16/25
Jefferies
Reiterated
04/15/25
Bank of America Securities
Reiterated
03/19/25
William Blair
Reiterated
03/17/25
TD Cowen
Reiterated
03/06/25
H.C. Wainwright
Reiterated
02/28/25
Wells Fargo
Reiterated
02/28/25
Wedbush
Reiterated
02/28/25
Deutsche Bank
Reiterated
02/28/25
Needham
Reiterated
02/28/25
Stifel Nicolaus
$62
Buy
83.54%
Upside
Reiterated
02/28/25
Stifel Nicolaus Remains a Buy on Xenon (XENE)
Leerink Partners
$50
Buy
48.02%
Upside
Reiterated
02/27/25
Promising Pipeline and Financial Stability Justify Buy Rating for Xenon
RBC Capital
$56
Buy
65.78%
Upside
Reiterated
02/26/25
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Eli Lilly & Co (NYSE: LLY) and Vaxcyte (NASDAQ: PCVX)
Robert W. Baird
$63
Buy
86.50%
Upside
Reiterated
11/12/24
Promising Prospects and Strategic Advances Drive Buy Rating for Xenon Pharmaceuticals
J.P. Morgan
―
Buy
―
Reiterated
10/24/24
Strong Growth Trajectory for Xenon Driven by Promising Clinical Pipeline and Differentiation Potential
Best Analysts Covering Xenon
Which Analyst Should I Follow If I Want to Buy XENE and Sell After:
1 Month
xxx
Success Rate
7/13 ratings generated profit
Average Return
+0.95%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 53.85% of your transactions generating a profit, with an average return of +0.95% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
+8.22%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +8.22% per trade.
1 Year
Success Rate
10/13 ratings generated profit
Average Return
+32.21%
reiterated a buy rating 3 days ago
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 76.92% of your transactions generating a profit, with an average return of +32.21% per trade.
2 Years
xxx
Success Rate
16/26 ratings generated profit
Average Return
+45.67%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 61.54% of your transactions generating a profit, with an average return of +45.67% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
XENE Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
1
0
5
5
7
Buy
14
12
14
15
14
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
15
12
19
20
21
Each month's total comprises the sum of three months' worth of ratings.
XENE Financial Forecast
XENE Stock Forecast FAQ
What is XENE’s average 12-month price target, according to analysts?
Based on analyst ratings, Xenon Pharmaceuticals’s 12-month average price target is $55.00.
What is XENE’s upside potential, based on the analysts’ average price target?
Xenon Pharmaceuticals has 62.82% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is XENE a Buy, Sell or Hold?
Xenon Pharmaceuticals has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
What is Xenon Pharmaceuticals’s price target?
The average price target for Xenon Pharmaceuticals is $55.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $65.00 ,the lowest forecast is $42.00. The average price target represents 62.82% Increase from the current price of $33.78.
The highest analyst price target is $65.00 ,the lowest forecast is $42.00. The average price target represents 62.82% Increase from the current price of $33.78.
What do analysts say about Xenon Pharmaceuticals?
Xenon Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of XENE?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.